Single domain antibodies targeting pathological tau protein: Influence of four IgG subclasses on efficacy and toxicity.

ABSTRACT:

Background

Eleven tau immunoglobulin G (IgG) antibodies have entered clinical trials to treat tauopathies, including Alzheimer's disease, but it is unclear which IgG subclass/subtype has the ideal efficacy and safety profile. Only two subtypes, with or without effector function, have been examined in the clinic and not for the same tau antibody. The few preclinical studies on this topic have only compared two subtypes of one antibody each and have yielded conflicting results.

Methods

We selected two single domain antibodies (sdAbs) derived from a llama immunized with tau proteins and utilized them to generate an array of Fc-(sdAb)₂ subclasses containing identical tau binding domains but differing Fc region. Unmodified sdAbs and their IgG subclasses were tested for

SUBMITTER: Congdon EE 

PROVIDER: S-EPMC9475275 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature